7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,817.45

+352.45

+0.45%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

OTC Markets OTCPK - Delayed Quote USD

Galderma Group AG (GALDY)

46.59 +0.60 (+1.30%)

At close: October 30 at 4:00:00 PM EDT

Loading Chart for GALDY

Chart Range Bar

Interval:

In partnership with ChartIQ

Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.

Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.

Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?

Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?

What Makes Galderma Group AG - Unsponsored ADR (GALDY) a New Strong Buy Stock

What Makes Galderma Group AG - Unsponsored ADR (GALDY) a New Strong Buy Stock

Galderma (SWX:GALD) Stock Could Be 39% Undervalued Following China Approval

Galderma (SWX:GALD) Stock Could Be 39% Undervalued Following China Approval

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines

Galderma raises 2026 sales growth outlook after Q3 revenue beats forecasts

Galderma raises 2026 sales growth outlook after Q3 revenue beats forecasts

Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance

Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance

AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership

AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis

Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering

Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering

Galderma to buy Blackstone-owned ZO Skin Health for $1.5 bln

Galderma to buy Blackstone-owned ZO Skin Health for $1.5 bln

Mobilize your Website

View Site in Mobile | Classic

Share by: